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Pyroglutamic Acidosis: 
A Rare and Underdiagnosed Cause of HIgh Anion Gap Metabolic Acidosis
Brigid Hallinan, DO; Tina Casey, DO; Matthew McCambridge, MD
High anion gap metabolic acidosis (HAGMA) is a common metabolic disorder 
encountered in the ICU setting. A likely underdiagnosed cause of HAGMA 
is pyroglutamic acidosis (5-oxoprolinuria), a condition caused by a defect in 
the gamma-glutamyl cycle.  Initially recognized as the result of a hereditary 
enzyme deficiency leading to significant metabolic abnormalities early in life, 
an increasing number of pyroglutamic acidosis cases have been reported in 
previously unaffected adults due to an acquired defect in the gamma-glutamyl 
cycle, nearly all associated with acetaminophen use. We present the case 
of a patient who developed severe pyroglutamic acidosis while on chronic 
acetaminophen therapy. 
Introduction: Table 1.  Pertinent Lab Values
Chemistry Urinalysis
Glucose 67 mg/dL Specific gravity 1.015
BUN 15 mg/dL PH 5
Cr 1.3 mg/dL Protein 100-200 mg/dL
Na+ 130 meq/L Ketone 40-60 mg/dL
K+ 5.8 meq/L Glucose negative
Cl- 100 meq’L Blood 0.06-0.10 mg/dL
HCO3 9 meq/L Leukocyte esterase negative
Anion gap 21 Nitrite negative
Ca2+ 11.6 mg/dL  
P3- 1.4 mg/dL Toxicology
Mg2+ 2.5 mg/dL Urine toxicology screen negative
Aetaminophen <10 ug/mL
Arterial Blood Gas Salicylates <1 mg/dL
pH 7.02 Methanol negative
pCO2 <20 mmHg Ethanol negative
pO2 161 mmHg Ethylene glycol negative
pHCO3 <5 meq/L
Base deficit 25.7 Other
02 sat, arterial 99% Lactate 1.6
Acetone negative
B-hydroxybutyric acid 0.89mmol/L
Serum osmolarity 281 mosm/kg
Urine anion gap 32
SPEP negative
D-lactate negative
Pyrolutamic acid 3767 umol/mmol or creatinine (Ref range 15-215)
History:  A 58-year-old Caucasian female presented to the emergency 
department complaining of a three-day history of rapidly progressive dyspnea.  
Review of systems was positive for poor oral intake, headache, dyspnea, 
chest tightness, and two episodes of vomiting.  Past medical history included 
hypertension, peptic ulcer disease, chronic low back pain, depression, and 
anxiety.  She denied any known history of renal disease.  Medications included 
omeprazole, duloxetine, aripiprazole, lorazepam, amitriptyline, melatonin, 
hydrocodone/acetaminophen and acetaminophen.  She noted that she had 
been recently taking a significantly increased amount of acetaminophen for 
pain.  The patient cited a 40 pack-year smoking history and quit ten years ago.  
She denied ingestion of ethanol, methanol, paraldehyde, ethylene glycol, or any 
illicit substances.  
Physical Exam:  Vital signs on admission were as follows: 97.4°F, blood 
pressure 142/72, pulse 143, respirations 28, and oxygen saturation 99% on 
room air.  Physical examination simply revealed a well-nourished but acutely ill-
appearing female in mild respiratory distress. 
Diagnostic Data: Initial laboratory studies (Table 1) revealed a high 
anion gap metabolic acidosis with pH 7.02, HCO3 9, and anion gap 21. Workup 
was negative for elevated lactate or salicylate levels, ketoacidosis, uremia, 
or evidence of methanol or ethylene glycol poisoning. The urine organic acid 
screen revealed a markedly elevated level of pyroglutamic acid.
Clinical Course:  Based on the patient’s laboratory studies and 
clinical findings, she was diagnosed with pyroglutamic acidosis associated 
with acetaminophen ingestion.  Her acidosis resolved with discontinuation 
of all acetaminophen-containing compounds, volume resuscitation, and 
administration of intravenous sodium bicarbonate. The patient rapidly improved 
with treatment and was discharged home in stable condition on the fourth 
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Pathogenesis:  Pyroglutamic acidosis occurs as a result of a defect in 
the gamma-glutamyl cycle.  This cycle is composed of a series of enzymatic 
reactions that ultimately leads to the production of the tripeptide glutathione, 
which serves an important role in many cells of the body- scavenging free 
oxygen radicals, drug detoxification, and amino acid transport (Figure 1).  
When normal or high levels of glutathione are present, the production of 
its precursor molecules is inhibited by negative feedback on the enzyme 
gamma-glutamylcysteine synthetase.  With chronic acetaminophen use, 
however, glutathione stores can be depleted, leading to up-regulation of 
gamma-glutamylcysteine synthetase and increased production of gamma-
glutamylcysteine.  This molecule is normally then converted to glutathione 
by glutathione synthetase.  However, with significant elevation in gamma-
glutamylcysteine levels, conversion to glutathione becomes the rate-limiting 
step1 and some gamma-glutamylcysteine enters the secondary metabolic 
pathway to be converted to 5-oxoproline (pyroglutamic acid)2.  It is the build-up 
of this molecule that leads to severe high anion gap metabolic acidosis.
Risk Factors:  There are several risk factors that have been implicated in 
the development of pyroglutamic acidosis, particularly when combined with use 
of acetaminophen.  These include sepsis, alcohol abuse, renal failure,3 hepatic 
dysfunction, malnutrition, prematurity, pregnancy,4  severe burns, Stevens-
Johnson syndrome, urea cycle disorders, hawkinsinuria, homocysteinuria, and 
artificial diets.1  Certain medications, including netilmicin, flucloxacillin, and 
vigabatrin, have also been linked to the disorder.3,5  The reason for our patient’s 
sudden development of severe metabolic acidosis after many years of being 
stable on chronic acetaminophen therapy was unclear but may have been 
precipitated by an increase in acetaminophen intake in the setting of acute 
malnutrition.  
Diagnosis: Diagnosis is made by recognition of high anion gap 
metabolic acidosis not explained by another etiology and either positive gas 
chromatography or detection of an elevated pyroglutamic acid level on a 
urine organic acid screen.  Acetaminophen level may be checked in order to 
rule out overdose, however, a low or undetectable acetaminophen level does 
not rule out pyroglutamic acidosis, as most cases do occur in patients taking 
therapeutic doses of acetaminophen.
Treatment:  Initial management involves discontinuation of all 
acetaminophen-containing medications, reversal of severe metabolic acidosis 
by administration of bicarbonate-containing intravenous fluids and treatment of 
any co-morbid conditions.  Intravenous N-acetylcysteine, the standard therapy 
for acetaminophen poisoning, may be of some benefit in the management of 
acquired pyroglutamic acidosis.  This has not been well studied.  However, 
with its possible therapeutic benefit in repleting glutathione stores and its 
low potential for toxicity, its use as an adjunctive measure does not seem 
unreasonable.
Discussion:
The diagnosis of pyroglutamic acidosis should be considered in the differential 
for any patient presenting with high anion gap metabolic acidosis, particularly 
if there is a history of recent acetaminophen use.  Increased awareness and 
prompt recognition of this condition by physicians can prevent fatal outcomes 
and recurrences in susceptible patients. 
Conclusion:
Figure 1.  The Gamma-glutamyl Cycle
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